Huaying Morning News | Q2 Earnings Season Kicks Off! U.S. Stocks Rose Over 2% Last Week; Hong Kong Stock Market Suspended Today Due to Typhoon Talim

This week, major companies including Tesla and Netflix will release their earnings reports. On Friday, most popular Chinese概念股 (U.S.-listed Chinese stocks) declined broadly: the Nasdaq Golden Dragon China Index fell 2.17%, yet rose 6.64% for the week. On Tuesday (July 18), Bank of America, Morgan Stanley, and Charles Schwab will release earnings before the U.S. market opens; on Wednesday, ASML, Goldman Sachs, and UBS Group will report pre-market, while Tesla, Netflix, and Zions Bancorporation will report after the market closes; on Thursday, TSMC will release earnings before the U.S. market opens. Hong Kong Stock Market Suspended Due to Typhoon Talim The Hang Seng Index rose 0.33% on Friday last week, gaining over 1,000 points for the week. Auto parts stocks stood out: Zhejiang Shibo (01057.HK) surged over 40% for the week and more than 74% month-to-date; Nexteer Automotive (01316.HK) rose over 17% for the week and over 30% month-to-date; newly listed Yaoshi Bang (09885.HK) jumped over 36% for the week—analysts suggest it may be included in the Stock Connect program by early September. Hot weather provided a boost: Dongyue Group (00189.HK), a leading refrigerant manufacturer, rose over 23% for the week. This week, China Evergrande and Kimbee Holdings will release earnings. Due to Typhoon Talim, the Hong Kong Exchanges and Clearing (HKEX) suspended trading across all Hong Kong equities—including Stock Connect—and derivatives markets for the entire day. New Listings in Hong Kong and U.S. Markets Hong Kong: 1) Xin Chuan Planning (01284.HK) had planned to list today but postponed due to the typhoon-induced suspension of Hong Kong trading. Its Hong Kong public offering was oversubscribed 44.2 times. In Friday’s dark pool trading, its shares surged as much as 19% on some brokers’ quotes and closed up 2.17%, generating HK$100 profit per lot. 2) Zhong’an Smart Living (02271.HK) announced issuance of approximately 127 million shares at HK$1.18 per share; each lot comprises 2,000 shares. The public offering was oversubscribed 1.84 times, with a 50% allotment rate for one-lot applicants. Listing is expected on July 18. U.S. Markets: 1) Among three IPOs that priced last Friday, Apogee Therapeutics (APGE)—a biotech focused on inflammatory diseases—performed strongest, surging over 28% intraday and closing up 24.88% at $21.23, with a market cap exceeding $1 billion. Nabors Energy Transition Corp. II (NETDU), a special purpose acquisition company (SPAC), closed up 1.1%. Sagimet Biosciences Inc. (SGMT), a biotech targeting liver disease and cancer, edged down 0.31%. 2) BioNexus Gene Lab Corp. (BGLC), a supplier of raw materials and blood testing services, is expected to list tonight. Additional companies—including ODD, SRM, WRNT, and FTEL—are also expected to go public later this week. Disclaimer: This article does not constitute any investment advice nor is it tailored to any individual investor’s specific investment objectives, financial situation, or particular needs.

Gene Editing Sector Surges: Industrial Opportunities Coexist with Commercialization Challenges

History of Drug Evolution — Source: Intellia Therapeutics, BOC International Securities Domestically, Bioray Biotech’s BRL-101 targets beta-thalassemia and sickle cell disease. It is currently undergoing a nationwide multicenter Phase II registration trial—the most advanced domestically developed gene-editing therapy nearing commercialization. Meanwhile, a collaborative clinical trial for Duchenne muscular dystrophy (DMD), led by the National Center for Children’s Health and other institutions, has shown promising progress: follow-up data indicate successful restoration of dystrophin expression in enrolled pediatric patients, along with marked improvements across multiple functional metrics. This therapy leverages an indigenous Chinese RNA editing technology and holds potential for expansion to additional disease indications. Overall, gene-editing therapeutics—among the most cutting-edge frontiers in pharmaceutical R&D—are progressively transitioning from research into real-world application. III. Upstream Leaders Clearly Defined; Therapies Expected to Launch Next Year Focusing on listed companies, we analyze the industry chain segment by segment. A representative upstream raw material supplier is #Novoprotein (688105.SH), which manufactures essential functional proteins for gene editing—including Cas proteins and reverse transcriptases—primarily under its biological reagents—protein business line. In 2025, Novoprotein achieved RMB 1.104 billion in revenue from its biopharmaceutical products business, with a gross margin of 74.91%, remaining broadly stable quarter-on-quarter. Based on annual report disclosures estimating the proportion attributable to protein-based biopharmaceuticals, this segment generated approximately RMB 330 million in revenue. Although Novoprotein does not separately disclose gene-editing-related product sales, as a key “water seller” (enabler) in the ecosystem, its earnings visibility remains relatively high. Novoprotein Product Portfolio — Source: Company Website #Orna Therapeutics (688238.SH) is a comparatively rare A-share CDMO provider specializing in cell and gene therapies. Its core strength lies in offering end-to-end viral vector solutions compatible with CRISPR gene editing—a critical and hard-to-replace link in the gene-editing value chain. In 2025, Orna disclosed it had cumulatively undertaken over 650 CDMO projects, with new orders exceeding RMB 130 million. While not all relate to gene editing, overall operational scale continues expanding: total annual revenue rose 7.88% year-on-year to RMB 268 million, and net losses narrowed by RMB 87 million. Tianze YunTai—a biopharma firm founded in 2020 whose IPO application was recently accepted—has two most advanced gene therapy candidates: one targeting aromatic L-amino acid decarboxylase (AADC) deficiency, and another for bietti crystalline dystrophy (BCD). Both are projected to gain domestic approval in 2027. The company also maintains pipeline development in neurodegenerative diseases. Although Tianze YunTai has no approved products yet, it has already generated over RMB 20 million in revenue through technology licensing. Moreover, its controlling shareholder has made binding commitments—for instance, extending the lock-up period by one year if no product receives regulatory approval by the end of 2027—demonstrating strong confidence in timely commercialization. IV. Commercialization Prospects Still Face Challenges Indeed, for biopharma firms, the gene-editing field offers considerable upside potential: in 2025, Eli Lilly announced its acquisition of Verve Therapeutics for up to $1.35 billion. Yet this sector faces persistent challenges. First, most approved and pipeline therapies target hematologic disorders and rare diseases—narrow patient populations. Second, manufacturing such therapies at scale remains difficult, resulting in exceptionally high costs.

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Jul 27, 2026

BioNexus Gene Lab Corp (BGLC) presents earnings forecasts for future EPS and revenue growth, updated on July 26, 2026. The report includes financial health indicators and TradingKey stock scores.

TradingKey

2026-05-12

BioNexus Gene Lab Corp (BGLC)

2026-06-18

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

2026-06-18

BioNexus Gene Lab Corp (BGLC) Institutional Confidence

2026-06-18

BioNexus Gene Lab Corp (BGLC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-06-18

BioNexus Gene Lab Corp Announces 10-to-1 Merger Stock Split